

# Predictive significance of circulating tumor DNA against patients with T790M- positive EGFR-mutant NSCLC receiving osimertinib

**Ou Yamaguchi**

Saitama Medical University

**Norimitsu Kasahara** (✉ [m14702016@gunma-u.ac.jp](mailto:m14702016@gunma-u.ac.jp))

Gunma University Hospital

**Hiroshi Soda**

Sasebo General Medical Center

**Hisao Imai**

Gunma Prefectural Cancer Center

**Ichiro Naruse**

Hidaka Hospital

**Hiroyuki Yamaguchi**

Nagasaki University Hospital

**Miki Itai**

Takasaki General Medical Center

**Kohei Taguchi**

Takasaki General Medical Center

**Megumi Uchida**

Takasaki General Medical Center

**Noriaki Sunaga**

Gunma University Graduate School of Medicine

**Toshiaki Maeno**

Gunma University Graduate School of Medicine

**Koichi Minato**

Gunma Prefectural Cancer Center

**Hiromi Tomono**

Sasebo General Medical Center

**Daiki Ogawara**

Sasebo General Medical Center

**Hiroshi Mukae**

Nagasaki University Hospital

**Yu Miura**

Saitama Medical University

**Ayako Shiono**

Saitama Medical University

**Atsuto Mouri**

Saitama Medical University

**Hiroshi Kagamu**

Saitama Medical University

**Kyoichi Kaira**

Saitama Medical University

---

## Article

**Keywords:** circulating tumor DNA, T790M, EGFR mutation, NSCLC, osimertinib

**Posted Date:** April 14th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1517908/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Additional Declarations:** Competing interest reported. KK, NK and NS have received research grants and a speaker honorarium from Nihon Medi-Physics Co.,Ltd and AstraZeneca.OY, AM and HK has received research grants and a speaker honorarium from AstraZeneca. All other authors declare no potential conflict of interest.

---

**Version of Record:** A version of this preprint was published at Scientific Reports on November 27th, 2023.

See the published version at <https://doi.org/10.1038/s41598-023-48210-5>.

# Abstract

**Background:** Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. Data regarding the predictive significance of ctDNA after first-line epidermal growth factor receptor (*EGFR*) tyrosine kinase inhibitors (TKIs) are limited. Thus, this study analyzed ctDNA during osimertinib administration as a second-line or greater setting to examine the association between *EGFR* mutation levels and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).

**Methods:** Forty patients with *EGFR* T790M-positive NSCLC receiving osimertinib after prior *EGFR*-TKI treatment were enrolled. Plasma samples were obtained at osimertinib pretreatment, after 1 month of treatment, and at the time of progressive disease (PD). ctDNA analysis was performed using digital polymerase chain reaction.

**Results:** The detection rate of copy numbers of exon 19 deletion, L858R, and T790M in plasma samples was significantly lower 1 month after osimertinib treatment than at pretreatment and significantly higher at PD than at 1 month, whereas that of C797S was significantly higher at PD than at 1 month. There was no statistically significant difference in the copy numbers of exon 19 deletion, L858R, T790M, and C797S between complete response or partial response and stable disease or PD.

T790M detection at PD after osimertinib initiation was a significant independent prognostic factor for predicting worse prognosis, and the presence of major *EGFR* mutations at pretreatment and PD was closely associated with shorter survival after osimertinib initiation.

**Conclusion:** Molecular testing based on ctDNA is useful for predicting outcomes of osimertinib treatment in T790M-positive NSCLC after previous *EGFR*-TKI treatment.

## Introduction

Molecular targeting agents are useful to improve the prognosis of patients with cancer with driver mutations [1]. Among patients with advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (*EGFR*) mutation is identified as the predominant target, and *EGFR* tyrosine kinase inhibitor (TKI) administration is the standard treatment for patients with NSCLC harboring *EGFR* mutation. In particular, osimertinib, as a third-generation *EGFR*-TKI, is administered as a first-line treatment [2], but it can also be effective for patients with previously treated NSCLC harboring T790M-positive *EGFR* mutation, based on the AURA3 trial [3]. If T790M is detected in progressive disease (PD) after first- or second-generation *EGFR*-TKI administration, osimertinib is applicable to such patients. However, approximately 25% of patients resistant to first- or second-generation *EGFR*-TKIs can receive osimertinib because of T790M-positive testing [4]. As the presence of T790M within tumor specimens cannot predict the outcome of osimertinib administration, the development of an useful predictor is required to distinguish responders from non-responders.

Recently, Ariyasu *et al.* evaluated the ratio of T790M to EGFR-activating mutations in cytological samples from 33 patients with NSCLC receiving osimertinib using droplet digital polymerase chain reaction (PCR) and found a significant correlation between the T790M ratio and the tumor reduction rate [5]. In addition, the clearing of all EGFR mutations from the blood after osimertinib initiation significantly predicted its efficacy and outcome in 82 pretreated patients receiving osimertinib, and all clearing of T790M and sensitizing mutations is necessary for a positive predictor of osimertinib [6].

The assessment of cell-free DNA (circulating tumor DNA [ctDNA]) is a noninvasive strategy for cancer diagnosis; in particular, plasma ctDNA testing to examine sensitizing *EGFR* and T790M mutations was approved in 2015 [7]. *EGFR* and T790M plasma testing was evaluated using several techniques, such as PCR and next-generation sequencing. Although liquid biopsy is more feasible than tissue biopsy, there are some doubts about the sensitivity of its detection. Digital PCR is a recently developed method. It has higher detection sensitivity than conventional PCR and has recently attracted attention for the detection of ctDNA [8, 9]. In several studies, the ratio of T790M to *EGFR*-activating mutations in ctDNA, plasma pretreatment T790M level, and fraction of *EGFR*-mutant ctDNA in plasma have been reported to be potential markers of prognosis in patients receiving osimertinib [10–12]. However, there are no established markers to predict the outcome of osimertinib treatment in patients with T790M-positive *EGFR* mutation.

Based on this background, we conducted a prospective study to investigate the predictive markers of osimertinib in patients with T790M-positive *EGFR*-mutant NSCLC using digital PCR.

## Results

### Patient demographics:

Patient demographics are shown in Table 1. Twenty-four patients had exon 19 deletion, 15 harbored L858R, and one patient presented with L861Q, as detected using the Cobas method. Forty blood samples were collected from patients before osimertinib initiation, 36 blood samples were collected from patients 1 month after osimertinib administration, and 20 blood samples were collected from patients with PD after osimertinib treatment. Nine of the 40 patients achieved no recurrence after treatment, whereas 31 patients experienced PD. The median age was 69 (range, 33–85) years, and 28 (70.0%) patients were women. Thirty-one (77.6%) patients were never-smoker, 35 (87.5%) had a performance status (PS) score of 0–1, and all patients were classified as having adenocarcinoma histology. Thirty-four (85%) patients had stage III or IV disease, and 6 (15%) patients had postoperative recurrence.

Table 1  
Patient's demographics

Different variables		N = 40 (%)
Age (year)	Median (range)	69 (33–85)
Gender	Male / Female	12 / 28 (30.0 / 70.0)
Clinical stage	III / IV / Ope rec.	4 / 30 / 6 (10.0 / 75.0 / 15.0)
Smoking history	Yes / No	9 / 31 (22.4 / 77.6)
ECOG PS	0–1 / 2	35 / 5 (87.5 / 12.5)
Histology	AC / other	40 / 0 (100 / 0)
EGFR mutation status	Exon 19 / L858R / L861Q	24 / 15 / 1 (60.0 / 37.5 / 2.5)
Numbers of prior treatment	1 / 2 or more lines	29 / 11 (72.5 / 27.5)
Prior EGFR-TKIs regimens	Gefitinib / Erlotinib / Afatinib	11 / 12 / 17 (27.5 / 30.0 / 42.5)
Brain metastases	Yes / No	17 / 23 (42.5 / 57.5)
PD-L1 expression	≥ 50% / <50% / unknown	1 / 17 / 22 (2.5 / 42.5 / 55.0)
Abbreviations:		
ECOG, eastern cooperative oncology group; PS, performance status; PD-L1, programmed death ligand-1; AC, adenocarcinoma; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; Ope rec., recurrence after operation.		

## EGFR mutation assessment in plasma circulating tumor DNA (ctDNA) samples:

In the exon 19 deletion assay, the copy numbers detected in plasma samples at pretreatment, at 1 month, and at PD after osimertinib treatment ranged from 0 to 77.5 (positive rate, 42.5% [17/40]), from 0 to 0.59 (positive rate, 13.9% [5/36]), and from 0 to 13.15 copies/uL (positive rate, 45.0% [9/20]), respectively, demonstrating a significant difference between 1 month and PD ( $p = 0.003$ ) (Fig. 1A). In the L858R assay, the copy numbers in the plasma sample at pretreatment, at 1 month, and at PD after treatment ranged from 0 to 134.7 (positive rate, 37.5% [15/40]), from 0 to 2.41 (positive rate, 13.9% [5/36]), and from 0 to 10.83 copies/uL (positive rate, 40.0% [8/20]), respectively, indicating a significant difference between 1 month and PD ( $p = 0.044$ ) (Fig. 1B). The copy numbers detecting T790M ranged from 0 to 93.9 at pretreatment (positive rate, 60.0% [24/40]), from 0 to 0.45 at 1 month (positive rate, 13.9% [5/36]), and from 0 to 5.67 copies/uL (positive rate, 45.0% [9/20]). There was a significant difference in the copy numbers between pretreatment and 1 month ( $p = 0.028$ ) and between 1 month and PD ( $p = 0.006$ ) (Fig. 1C). The copy numbers of C797S ranged from 0 to 0.18 at pretreatment (positive rate, 12.5% [5/40]), from 0 to 0.09 at 1 month (positive rate, 11.1% [4/36]), and from 0 to 0.31 at PD (positive rate, 30.0% [6/20]), and those at PD were significantly higher than those at 1 month ( $p = 0.025$ ) (Fig. 1D). Moreover, the positive rate of copy numbers of exon 19 deletion, L858R, and T790M in plasma samples were significantly lower at 1 month after osimertinib treatment than at pretreatment and PD, whereas that of C797S was significantly higher at PD than at 1 month (Fig. 2).

## Association between plasma ctDNA and efficacy to osimertinib:

Of the 40 patients, one achieved a complete response (CR), 24 had a partial response (PR), 11 had stable disease (SD), 3 displayed PD, and one had a non-evaluable lesion. The overall response rate (ORR) and disease control rate were 64.1% (25/39) and 92.3% (36/39), respectively. A comparison of the copy numbers based on the exon 19 deletion, L858R, T790M, and C797S between CR or PR (responders) and SD or PD (non-responders) was performed. However, there was no statistically significant difference in the copy numbers between them (Fig. A, online only). In addition, the positive rate of copy number did not differ significantly between responders and non-responders, except for exon 19 deletion at pretreatment (Fig. B, online only).

## Survival analysis according to plasma ctDNA:

The median PFS and OS were 13.1 months and 27.2 months, respectively. Twenty-five (62.5%) of the 40 patients experienced recurrence, and 19 (47.5%) patients died due to disease progression. Univariate and multivariate analyses were performed in all patients (Tables 2 and 3). Univariate analysis identified the detection of major *EGFR* mutation (exon 19 deletion and L858R) at pretreatment and detection of T790M at PD after osimertinib treatment for PFS (Table 2), and PS, brain metastasis, detection of major *EGFR* mutation at PD, and detection of T790M at PD after its treatment were considered significant predictors for OS (Table 3). Multivariate analysis confirmed that detection of major *EGFR* mutation at pretreatment and detection of T790M at PD were independent prognostic factors for predicting favorable PFS (Table 2), and detection of T790M at PD was identified as an independent factor for predicting better OS

(Table 3). Kaplan–Meier curves for PFS and OS according to the detection of major *EGFR* mutation and T790M are shown in Fig. 3A and 3B.

Table 2  
Univariate and multivariate analysis in progression-free survival

Different variables		Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age	< 65 / ≥65	1.10 (0.46–2.50)	0.81		
Gender	Male / Female	0.96 (0.37–2.25)	0.94		
Smoking history	Ever / Never	0.63 (0.18–1.67)	0.37		
ECOG PS	0–1 / 2	0.23 (0.05–1.61)	0.12		
EGFR mutation	Ex19 del / L858R	0.94 (0.40–2.30)	0.90		
Line of previous treatment	2 / ≥3	0.46 (0.18–1.18)	0.10		
Brain metastasis	Yes / No	1.51 (0.66–3.41)	0.31		
Detection of major mt (pre)	Yes / No	2.81 (1.14–8.52)	<b>0.02</b>	7.17 (1.37–13.2)	<b>0.01</b>
Detection of major mt at 1M	Yes / No	0.78 (0.28–1.87)	0.60		
Detection of major mt at PD	Yes / No	0.99 (0.38–2.71)	0.99		
Detection of T790M (pre)	Yes / No	1.86 (0.88–4.22)	0.10		
Detection of T790M at 1M	Yes / No	1.04 (0.29–2.82)	0.94		
Detection of T790M at PD	Yes / No	4.45 (1.49–14.86)	<b>&lt; 0.01</b>	6.17 (1.94–22.5)	<b>&lt; 0.01</b>
Detection of C797S (pre)	Yes / No	1.46 (0.42–3.87)	0.50		

Abbreviations: ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; major mt, major EGFR mutation (exon 19 deletion or L858R); (pre), at pretreatment; 1M, 1 month after osimertinib administration; PD, progressive disease after osimertinib administration; HR, hazard ratio; 95% CI, 95% confidence interval; Decrease of plasma major mt; decrease of major EGFR mutation in plasma samples from pretreatment to 1 month after osimertinib administration; Decrease of plasma T790M, decrease of T790M in plasma samples from pretreatment to 1 month after osimertinib administration.

Different variables		Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Detection of C767S at 1M	Yes / No	1.86 (0.53–4.03)	0.29		
Detection of C797S at PD	Yes / No	1.53 (0.52–4.03)	0.41		
Decrease of plasma major mt	Yes / No	2.32 (0.97–6.45)	0.05		
Decrease of plasma T790M	Yes / No	1.65 (0.75–3.83)	0.21		
<p>Abbreviations: ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; major mt, major EGFR mutation (exon 19 deletion or L858R); (pre), at pretreatment; 1M, 1 month after osimertinib administration; PD, progressive disease after osimertinib administration; HR, hazard ratio; 95% CI, 95% confidence interval; Decrease of plasma major mt; decrease of major EGFR mutation in plasma samples from pretreatment to 1 month after osimertinib administration; Decrease of plasma T790M, decrease of T790M in plasma samples from pretreatment to 1 month after osimertinib administration.</p>					

Table 3  
Univariate and multivariate analysis in overall survival

Different variables		Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age	< 65 / ≥65	0.44 (0.12–1.21)	0.11		
Gender	Male / Female	0.52 (0.15–1.45)	0.23		
Smoking history	Ever / Never	0.55 (0.12–1.68)	0.32		
ECOG PS	0–1 / 2	0.07 (0.20–0.28)	<b>&lt; 0.01</b>	0.68 (0.12–5.19)	0.68
EGFR mutation	Ex19 del / L858R	0.68 (0.26–1.83)	0.44		
Line of previous treatment	2 / ≥3	0.39 (0.15–1.03)	0.05		
Brain metastasis	Yes / No	2.93 (1.14–7.87)	0.02	2.45 (0.48–19.2)	0.29
Detection of major mt (pre)	Yes / No	1.51 (0.54–5.37)	0.45		
Detection of major mt at 1M	Yes / No	0.77 (0.17–2.45)	0.69		
Detection of major mt at PD	Yes / No	4.50 (1.11–30.36)	<b>0.03</b>	0.61 (0.03–7.91)	0.71
Detection of T790M (pre)	Yes / No	2.39 (0.90–7.48)	0.07		
Detection of T790M at 1M	Yes / No	2.72 (0.61–8.79)	0.16		
Detection of T790M at PD	Yes / No	21.7 (3.81–409.2)	<b>&lt; 0.01</b>	22.4 (2.50–672)	<b>&lt; 0.01</b>
Detection of C797S (pre)	Yes / No	1.34 (0.31–4.09)	0.64		

Abbreviations: ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; major mt, major EGFR mutation (exon 19 deletion or L858R); (pre), at pretreatment; 1M, 1 month after osimertinib administration; PD, progressive disease after osimertinib administration; HR, hazard ratio; 95% CI, 95% confidence interval; Decrease of plasma major mt; decrease of major EGFR mutation in plasma samples from pretreatment to 1 month after osimertinib administration; Decrease of plasma T790M, decrease of T790M in plasma samples from pretreatment to 1 month after osimertinib administration.

Different variables		Univariate analysis		Multivariate analysis	
		HR (95% CI)	p-value	HR (95% CI)	p-value
Detection of C767S at 1M	Yes / No	2.47 (0.37–9.81)	0.29		
Detection of C797S at PD	Yes / No	0.88 (0.19–3.07)	0.85		
Decrease of plasma major mt	Yes / No	0.94 (0.33–3.06)	0.92		
Decrease of plasma T790M	Yes / No	1.86 (0.65–6.03)	0.24		

Abbreviations: ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; major mt, major EGFR mutation (exon 19 deletion or L858R); (pre), at pretreatment; 1M, 1 month after osimertinib administration; PD, progressive disease after osimertinib administration; HR, hazard ratio; 95% CI, 95% confidence interval; Decrease of plasma major mt; decrease of major EGFR mutation in plasma samples from pretreatment to 1 month after osimertinib administration; Decrease of plasma T790M, decrease of T790M in plasma samples from pretreatment to 1 month after osimertinib administration.

## Clinical efficacy on the ratio of T790M to major EGFR mutation:

The clinical significance of the T790M/major *EGFR* mutation ratio at pretreatment was investigated, with a mean of 0.305 for CR/PR/SD and 0.185 for PD, without a significant difference ( $p = 0.632$ ) (Fig. C1, online only). According to ROC analysis, the best cut-off value of the T790M/major *EGFR* mutation ratio was 0.727. No statistically significant difference in PFS and OS was observed between patients with T790M/major *EGFR* mutation  $\geq 0.727$  and  $< 0.727$  (Fig. C2 and C3, online only).

## Discussion

This was a prospective observational study evaluating the prognostic significance of ctDNA, such as exon 19 deletion, L858R, T790M, and C797S *EGFR* mutations, in patients with previously treated NSCLC harboring T790M *EGFR* mutation who received osimertinib. The detection of ctDNA in plasma samples by digital PCR exactly reflected the change in exon 19 deletion, L858R, and T790M at 1 month and PD after osimertinib administration. We found that the detection of T790M at PD after osimertinib initiation was a significant independent prognostic factor for predicting worse OS, and that the detection of major *EGFR* mutations at pretreatment and T790M at PD also affected the outcome after osimertinib initiation. Currently, osimertinib is clarified as a first-line EGFR-TKI; thus, the frequency of its administration as a second-line or more lines is decreasing. However, the detection of blood samples using digital PCR is a noninvasive technique that is convenient for daily practice, and an improvement in the detection rate is warranted to realize the development of an optimal predictor.

The analysis of *EGFR* mutation in tissue and plasma from the AURA3 trial reported that the detection of plasma T790M was related to a larger baseline tumor size, and PFS after osimertinib (median, 12.5 vs. 8.3 months) was longer in patients with a Cobas plasma T790M-negative status at pretreatment compared to those with a plasma T790M-positive status [14]. PFS in patients with NSCLC harboring T790M who received osimertinib tended to be worse in patients with high T790M copy number at pretreatment, as assessed by cell-free plasma DNA using digital, rather than those with low T790M copy number. Moreover, no significant difference in ORR was recognized according to T790M copy numbers [15]. Although another study also assessed the association between the utility of plasma T790M mutant copy number at pretreatment and the prognostic role of osimertinib using digital PCR, a high plasma T790M copy number was associated with worse PFS and OS compared to a low T790M copy number [16]. In addition, a high copy number of active *EGFR* mutations in plasma samples has been reported to be closely associated with poor outcomes after osimertinib treatment [11]. The results of these studies indicated that a high copy number of plasma T790M or activating *EGFR* mutations was a useful marker for predicting worse PFS in patients with NSCLC harboring positive *EGFR* T790M who were treated with osimertinib [11, 14–16]. Ding *et al.* reported that high plasma T790M level at pretreatment was related to superior disease control in patients with NSCLC with advanced *EGFR* T790M treated with osimertinib [10]. In our study, the detection of major plasma *EGFR* mutation (exon 19 deletion or L858R) at pretreatment could predict shorter PFS after osimertinib administration, but not plasma T790M copy number. Although previous studies have focused on the association between plasma *EGFR* mutation copy numbers and the efficacy of osimertinib at pretreatment, Sakai *et al.* evaluated the clinical significance of monitoring the ctDNA of *EGFR*-TKI-sensitizing mutations and *EGFR* T790M mutation in *EGFR* T790M-positive patients with NSCLC at pretreatment, on day 1 of treatment cycle 4 or 9, and at the diagnosis of PD using digital PCR [17]. In their study, rebound of sensitizing *EGFR* mutation and T790M was observed at PD, and ctDNA monitoring for sensitizing *EGFR* mutation at four cycles was better for predicting the outcome after osimertinib [17]. We found that the detection rate of ctDNA by digital PCR significantly decreased 1 month after osimertinib initiation, and that the detection of plasma T790M at PD was closely associated with worse outcomes. Although ctDNA monitoring in the early phase after osimertinib may not be useful for prognostic prediction, the detection of major *EGFR* mutation at pretreatment is predictive of PFS after osimertinib based on previous studies.

Several studies have investigated the prognostic significance of the ratio of T790M to major *EGFR* mutation at baseline in patients with advanced *EGFR* T790M-positive NSCLC receiving osimertinib and reported that a higher ratio is closely related to tumor shrinkage and favorable survival [11, 18]. Two researchers observed that the ratio was significantly higher in patients with CR/PR/SD than in those with PD [11, 18]. In the present study, the ratio of T790M/major *EGFR* mutation at pretreatment could not predict the outcome or tumor shrinkage after osimertinib administration. A previous study confirmed that the amount of plasma T790M at pretreatment is not a reliable biomarker for tumor response and survival [11, 18]. This finding is similar to the results of the present study. Although the absence of major *EGFR* mutation in plasma at pretreatment may be a significant surrogate marker for the outcome after

osimertinib treatment, we believe that baseline T790M level is not closely associated with response and prognostic prediction.

Our study has some limitations. First, the sample size was small, which may have biased the results. Second, the current study focused on patients harboring the T790M EGFR mutation after first- or second-generation EGFR-TKI administration. Currently, osimertinib is frequently administered to patients with naive EGFR-TKIs. Therefore, our digital PCR technique should be examined as an exploratory investigation for a predictive marker of first-line osimertinib. Moreover, we defined a copy number of 0 (copies/ $\mu$ L) as the cut-off value for further investigation. The cut-off values of copy number are different according to individual studies; therefore, it is uncertain whether an optimal cut-off value is determined by digital PCR. Finally, we were unable to investigate the mechanisms of resistance to osimertinib, except for C797S. Resistance mechanisms, such as the bypass signaling pathway, PTEN loss, MET amplification, MYC amplification, and small cell lung carcinoma transformation, have been described in previous reports [19–21]. Since resistance to osimertinib is closely associated with many tumor mutations, it is difficult to identify specific markers.

In conclusion, the detection of plasma T790M at PD after osimertinib treatment is identified as a significant predictor of worse outcomes after osimertinib administration. The detection of major *EGFR* mutations during pretreatment and PD also affects the outcome after treatment. Further investigation using a large-scale sample is warranted to confirm the results of our study.

## Methods

### Patients:

A total of 40 patients with advanced *EGFR* T790M-mutant NSCLC on PD after first- or second-generation EGFR-TKI administration were registered in a prospective, observational multicenter study from August 2016 to December 2019. The inclusion criteria in this study were as follows: age  $\geq$  20 years, cytologically or histologically confirmed NSCLC harboring *EGFR* mutations, PD after first- or second-generation EGFR-TKI (gefitinib, erlotinib, or afatinib) administration, and verified *EGFR* T790M mutation in liquid and/or tissue re-biopsy. Clinical data were extracted from the medical records. This study was conducted according to the international guidelines on Good Clinical Practice and the Declaration of Helsinki and was approved by the institutional ethics committee (Gunma University Hospital Clinical Research Review Board) on 4th of April, 2017. (Registration number: 1524) Written informed consent was obtained from all participating individuals.

### Treatment and evaluation:

All patients were treated with osimertinib 80 mg daily as a starting dose, with dose reductions or interruptions based on the clinician's discretion because of PD or therapeutic toxicity. Physical examination, complete blood count, biochemical testing, and adverse events were measured according to the judgment of each chief physician. Any toxicity was graded based on the Common Terminology

Criteria for Adverse Events version 4.0. Tumor response was examined according to the Response Evaluation Criteria in Solid Tumors version 1.1 [13].

## Blood sample collection and epidermal growth factor receptor (EGFR) mutation analysis:

Peripheral blood samples (20 mL) were collected in ethylenediaminetetraacetic acid tubes before pretreatment, 1 month after osimertinib treatment, and at PD. The samples were centrifuged at 3,000 rpm for 15 min at room temperature and stored at  $-80^{\circ}\text{C}$  until analysis. ctDNA was isolated using a cfDNA Sample Preparation Kit (Roche Molecular Systems).

EGFR mutation testing using Cobas was performed according to the manufacturer's protocol. Mutation analysis was performed by PCR using a Cobas z480 analyzer (Roche Molecular Systems).

Droplet digital PCR (Bio-Rad) was performed according to previously reported techniques [8], and sensitizing EGFR mutations, EGFR T790M, and EGFR C797S were detected. The primers and probe for the detection of sensitizing EGFR mutations and EGFR T790M were provided by Bio-Rad using the QUANTSOFT analytical software package (Bio-Rad). Primers and probes for detecting EGFR C797S were obtained from Riken Genetics.

## Statistical analyses:

For statistical analyses, we used Student's *t*-test and the  $\chi^2$  test for continuous and categorical variables, respectively. The statistical significance level was set at  $p < 0.05$ . Progression-free survival (PFS) was defined as the time from the day of initial osimertinib treatment to either earlier that of disease progression or death. Overall survival (OS) was defined as the time from the day of initial osimertinib treatment to that of death from any cause. The Kaplan–Meier method was used to estimate survival as a function of time, and survival differences were analyzed using the log-rank test. Univariate and multivariate analyses according to different variables were performed using logistic regression analysis. In this study, a copy number of 0 (copies/ $\mu\text{L}$ ) was defined as negative, and a copy number greater than 0 was defined as positive. The predictive value of T790M/major *EGFR* mutation ratio at pretreatment was determined by receiver operating characteristic (ROC) curve analyses, which were used for PFS to identify an optimal cut-off value. All statistical analyses were performed using GraphPad Prism (version 8.0; GraphPad Software, San Diego, CA, USA) and JMP 14.0 (SAS Institute Inc., Cary, North Carolina, USA).

## Declarations

***Funding:*** This study was funded by AstraZeneca. This work was supported by JSPS KAKENHI (Grant Number: JP19K16855).

***Data availability:*** The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Acknowledgements:** The authors thank Yosuke Miura, Yukiko Suto, and Takayuki Asao for their assistance in preparing this manuscript. The authors also thank Editage ([www.editage.jp](http://www.editage.jp)) for the English language editing.

**Author contributions:** OY, NK and KK: study conception and manuscript preparation. OY, HS, HI, IN, HY, MI, KT, MU, HT, DO, YM, AS and AM: patient management. NK, KK, NS, TM, KM, HM and HK: statistical analysis and patient data collection. OY, NK and KK: manuscript revision. All authors contributed and agreed with the content of the manuscript.

**Competing interests:** KK, NK and NS have received research grants and a speaker honorarium from Nihon Medi-Physics Co.,Ltd and AstraZeneca. OY, AM and HK has received research grants and a speaker honorarium from AstraZeneca.

All other authors declare no potential conflict of interest.


## References

1. Kris, M. G. *et al.* Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA* **311**, 1998–2006 (2014).
2. Soria, J. C. *et al.* Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N. Engl. J. Med.* **378**, 113–125 (2018).
3. Mok, T. S. *et al.* Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N. Engl. J. Med.* **376**, 629–640 (2017).
4. Seto, T. *et al.* Real-world EGFR T790M testing in advanced non-small-cell lung cancer: a prospective observational study in Japan. *Oncol. Ther.* **6**, 203–215 (2018).
5. Ariyasu, R. *et al.* High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. *Lung Cancer* **117**, 1–6 (2018).
6. Boysen Fynboe Ebert, E. *et al.* Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. *Lung Cancer* **143**, 67–72 (2020).
7. U.S. Food and Drug Administration. Medical Devices: cobas EGFR Mutation Test v2 - P150047. Available online. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150047>.
8. Kasahara, N. *et al.* Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer. *Lung Cancer* **106**, 138–144 (2017).
9. Oxnard, G. R. *et al.* Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. *Clin. Cancer Res.* **20**, 1698–1705 (2014).
10. Ding, P. N. *et al.* Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.

- Transl. Lung Cancer Res. **10**, 1623–1634 (2021).
11. Del Re, M. *et al.* The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response. *Br. J. Cancer* **119**, 1252–1258 (2018).
  12. Beagan, J. J. *et al.* Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment. *Lung Cancer* **145**, 173–180 (2020).
  13. Eisenhauer, E. A. *et al.* New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* (version 1.1) **45**, 228–247 (2009).
  14. Papadimitrakopoulou, V. A. *et al.* Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. *Cancer* **126**, 373–380 (2020).
  15. Buder, A. *et al.* Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC. *J. Thorac. Oncol.* **13**, 821–830 (2018).
  16. Li, J. Y. C., Ho, J. C. M. & Wong, K. H. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer. *Oncotarget* **9**, 27929–27939 (2018).
  17. Sakai, K. *et al.* Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). *Mol. Oncol.* **15**, 126–137 (2021).
  18. Bordi, P. *et al.* From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. *Lung Cancer* **131**, 78–85 (2019).
  19. Oxnard, G. R. *et al.* Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. *JAMA Oncol.* **4**, 1527–1534 (2018).
  20. Le, X. *et al.* Landscape of EGFR-dependent and –independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. *Clin. Cancer Res.* **24**, 6195–6203 (2018).
  21. Yang, Z. *et al.* Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. *Clin. Cancer Res.* **24**, 3097–3107 (2018).

## Figures


**Figure 1**



**Figure 1**


Distribution of epidermal growth factor receptor (*EGFR*) mutant-allele copy number in plasma samples before osimertinib (pretreatment), 1 month after its administration, and at progressive disease to its treatment, according to the *EGFR* mutation status of exon 19 deletion (A), exon 21 L858R (B), T790M (C), and C797S (D).

**Figure 2**



**Figure 2**

Comparison of positive rate of copy numbers in exon 19 deletion (A), L858R (B), T790M (C), and C797S (D), according to pretreatment, 1 month, and at progressive disease after osimertinib initiation.



### Figure 3

Kaplan–Meier curve according to major epidermal growth factor receptor (*EGFR*) mutation (**A**) and T790M (**B**) at pretreatment, 1 month, and progressive disease (PD) after osimertinib administration.

Patients with detection of major *EGFR* mutation at pretreatment exhibited a significantly shorter progression-free survival (PFS) than those without it; moreover, there was significantly worse overall survival (OS) in patients with detection of major *EGFR* mutation at PD than those without it (**A**). Patients with T790M detection at PD yielded significantly worse PFS and OS than those without it (**B**).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SuppFigures.pptx](#)